| Title: |
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup |
| Authors: |
Rubatto, Marco; Fava, Paolo; Stanganelli, Ignazio; Ribero, Simone; Pigozzo, Jacopo; Di Giacomo, Anna Maria; Ridolfi, Laura; Tronconi, Maria Chiara; Trojaniello, Claudia; Bersanelli, Melissa; Garutti, Mattia; Indini, Alice; De Risi, Ivana; De Tursi, Michele; Merelli, Barbara; Morgese, Francesca; Occelli, Marcella; Cappellini, Gian Carlo Antonini; Poletto, Stefano; Fedele, Dahlia; Brugnara, Sonia; Frisinghelli, Michela; Formisano, Luigi; Conca, Raffaele; Tucci, Marco; Russillo, Michelangelo; Ceroni, Luca; Queirolo, Paola; Targato, Giada; Strippoli, Sabino; Mandalà, Mario; Guida, Michele; Quaglino, Pietro |
| Contributors: |
Rubatto, Marco; Fava, Paolo; Stanganelli, Ignazio; Ribero, Simone; Pigozzo, Jacopo; Di Giacomo, Anna Maria; Ridolfi, Laura; Tronconi, Maria Chiara; Trojaniello, Claudia; Bersanelli, Melissa; Garutti, Mattia; Indini, Alice; De Risi, Ivana; De Tursi, Michele; Merelli, Barbara; Morgese, Francesca; Occelli, Marcella; Cappellini, Gian Carlo Antonini; Poletto, Stefano; Fedele, Dahlia; Brugnara, Sonia; Frisinghelli, Michela; Formisano, Luigi; Conca, Raffaele; Tucci, Marco; Russillo, Michelangelo; Ceroni, Luca; Queirolo, Paola; Targato, Giada; Strippoli, Sabino; Mandalà, Mario; Guida, Michele; Quaglino, Pietro |
| Publication Year: |
2023 |
| Collection: |
Università degli Studi di Siena: USiena air |
| Subject Terms: |
Discontinuation of immunotherapy; Metastatic melanoma therapy; Real-life study |
| Description: |
Background: Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1 (anti-Programmed cell death-1) therapy in metastatic melanoma patients remains to be elucidated. Moreover, limited data are available on clinical outcomes of patients that discontinued anti-PD1 immunotherapy in a real-life setting. The aim of this study was to evaluate the progression-free survival (PFS) in patients with metastatic melanoma who interrupted anti-PD-1 treatment in the in the absence of disease progression. Methods: We retrospectively reviewed patients with advanced/metastatic melanoma treated with anti-PD1 immunotherapy at 23 Italian Melanoma Intergroup (IMI) centres. The study investigated the risk of relapse in patients who stopped anti-PD1 therapy due to CR (Complete response), treatment-related toxicity, or by their own choice after a long period of treatment. Clinical and biological factors associated with or without recurrence were evaluated. Results: The study population included 237 patients. The median age of patients was 68.9years (standard deviation: 13; range 33-95). The median time on treatment was 33months (standard deviation: 18,7; range 1-98). Among the 237 patients, 128 (54%) interrupted the anti-PD1 for CR, 74 patients (31.2%) for adverse events (37 patients in CR, 27 patients in partial response (PR), ten patients in stable disease (SD), and 35 patients (14.8%) by their own choice (12 patients in CR, 17 patients in PR, and 6 patients in SD). After a mean follow-up of 21months (range 1-81), PFSafter anti-PD1 discontinuation was 85.7%. Thirty-four patients (14.3%) developed disease progression after a median of 12months (range 1-35): ten patients (29.4%) after discontinuation in CR, 17 patients (50%) after discontinuation for treatment-related toxicity (seven in CR, five in PR, five in SD), and seven (20.6%) after discontinuation due to the patient's decision ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
STAMPA |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/37099946; info:eu-repo/semantics/altIdentifier/wos/WOS:000994560100001; volume:187; firstpage:25; lastpage:35; numberofpages:11; journal:EUROPEAN JOURNAL OF CANCER; https://hdl.handle.net/11365/1232440; https://www.sciencedirect.com/science/article/pii/S0959804923001557 |
| DOI: |
10.1016/j.ejca.2023.03.020 |
| Availability: |
https://hdl.handle.net/11365/1232440; https://doi.org/10.1016/j.ejca.2023.03.020; https://www.sciencedirect.com/science/article/pii/S0959804923001557 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.551C8F91 |
| Database: |
BASE |